Oncolytics Biotech
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Oncolytics Biotech generated cash of -$28,448,000, which is less than the previous year. Cash used in financing activities reached the amount of $31,994,000 last year. Net change in cash is therefore $23,246,000.
Cash Flow
| 2014 | -19.67M | -182.79K | 9.04M |
|---|---|---|---|
| 2015 | -15.03M | -137.56K | 23.66M |
| 2016 | -12.47M | -51.35K | 956.13K |
| 2017 | -14.89M | 1.98M | 12.81M |
| 2018 | -11.92M | -107.46K | 13.29M |
| 2019 | -19.90M | -10.90K | 21.01M |
| 2020 | -22.06M | -29.30K | 39.77M |
| 2021 | -22.43M | -285.94K | 33.01M |
| 2022 | -23.35M | -20.40M | 12.20M |
| 2023 | -28.44M | 20.22M | 31.99M |
ONCY Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 11.66M | 41.26M | 31.21M | 14.14M | 13.69M | 11.83M | 12.03M | 24.01M | 14.15M | 25.22M |
Operating activities | ||||||||||
Net income | -27.75M | -24.83M | -26.30M | -22.50M | -33.12M | -17.03M | -15.61M | -15.13M | -13.72M | -18.61M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 403K | 392K | 452.06K | 446.18K | 485.57K | 95.37K | 90.76K | 162.23K | 180.41K | 163.50K |
Stock-based compensation expense | 2.06M | 2.37M | 3.82M | 2.55M | 1.47M | 0 | 578.70K | 406.07K | 429.53K | 980.32K |
| Deferred income tax benefit | 2.06M | 2.37M | 3.82M | 2.55M | 1.47M | 0 | 578.70K | 406.07K | 429.53K | 980.32K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 506K | 345K | -776.39K | 1.97M | -2.01M | 4.76M | -4.76M | 285.65K | -148.30K | -85.89K |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -28.44M | -23.35M | -22.43M | -22.06M | -19.90M | -11.92M | -14.89M | -12.47M | -15.03M | -19.67M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | -20.34M | 0 | 0 | 0 | 0 | 0 | -27.82K | -29.29K | 0 |
Investments In Property Plant And Equipment | -8K | -55K | -285.94K | -29.30K | -10.90K | -107.46K | -105.76K | -23.52K | -108.26K | -152.75K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 20.22M | -20.40M | -285.94K | -29.30K | -10.90K | -107.46K | 1.98M | -51.35K | -137.56K | -182.79K |
Financing activities | ||||||||||
Common Stock Issued | 31.62M | 12.57M | 32.91M | 38.29M | 17.99M | 13.17M | 12.46M | 956.13K | 23.66M | 9.04M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -407K | -381K | -365.51K | -460.72K | -447.49K | 0 | 0 | 0 | 19.36M | 0 |
Cash used in financing activities | 31.99M | 12.20M | 33.01M | 39.77M | 21.01M | 13.29M | 12.81M | 956.13K | 23.66M | 9.04M |
Net Change In Cash | 23.24M | -29.59M | 10.04M | 17.07M | 448.14K | 1.86M | -198.16K | -11.98M | 9.86M | -11.06M |
Cash at end of period | 34.91M | 11.66M | 41.26M | 31.21M | 14.14M | 13.69M | 11.83M | 12.03M | 24.01M | 14.15M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |